The Advisory Committee on Immunization Practices (ACIP) is convening an emergency meeting to discuss adverse events that recently led to thrombotic events in 6 women administered the Johnson & Johnson COVID-19 vaccine in the US.

The committee, meeting following the federal pause of Johnson & Johnson vaccine distribution by the US Food and Drug Administration (FDA), is addressing the matter of cerebral venous thrombosis risk among women aged 18-49 vaccinated with the one-shot prophylaxis.

But what is this concerning side effect—and what is its link to both COVID-19 and adenovirus-based vaccines designed to prevent the pandemic virus?

Read More